Lobbying Information
Subject Matters
- Consumer Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Trade
- Science and Technology
- Small Business
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Modernisation de la Loi sur les aliments et drogues en lien avec le développement d'un encadrement des licences pour les pharmaceutiques par Santé Canada
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
- The Patent Act with respect to the export of pharmaceuticals.
Policies or Program
- The federal Science and Technology Strategy with respect to pharmaceuticals and the important role competition palys in supporting innovation.
Regulation
- Poursuite juridique de l'Association canadienne du médicament générique (ACMG) relativement aux modifications faites en 2006 à la Loi sur les aliments et drogues.
- Proposed changes to the Patented Medicines (Notice of Compliance)
Regulations with respect to pharmaceuticals to adress the following operational concers : lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Canada Economic Development for Quebec Regions
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Employment and Social Development Canada (ESDC)
-
Environment and Climate Change Canada (ECCC)
-
Global Affairs Canada (GAC)
-
Hazardous Materials Information Review Commission (HMIRC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
-
Statistics Canada (StatCan)
-
Transport Canada (TC)
-
Veterans Affairs Canada (VAC)
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
120, rue Yonge, Bureau 409
Toronto, ON M2P 2B8
Canada
Telephone number:
416-223-2333
Fax number:
416-223-2425
Client representative
Jim Keon, Président
Parent Company Information
Canadian Generic Pharmaceutical Association / L'association canadienne du médicament générique is not a subsidiary of any other parent companies.
Coalition Members Information
Canadian Generic Pharmaceutical Association / L'association canadienne du médicament générique is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Canadian Generic Pharmaceutical Association / L'association canadienne du médicament générique are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Canadian Generic Pharmaceutical Association / L'association canadienne du médicament générique does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
Daniel Charron
|
No public offices held
Business address:
417, rue Saint-Pierre
Bureau 502
Montréal, QC H2Y 2M4
Canada
Telephone number:
514-286-6033
Ext.
236
Fax number:
514-286-6068
Consultant Firm and Address
Firm:
Octane - Architecture stratégique et communication
Address:
417, rue Saint-Pierre
Bureau 502
Montréal, QC H2Y 2M4
Canada
Telephone number:
514-286-6033
Ext.
236
Fax number:
514-286-6068
